ETF Managers Group’s Vir Biotechnology VIR Stock Holding History

ETF Managers Group’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$796K	Buy	34,187 +999	+3%	+$25.6K	0.03%	272
2022 Q4	$840K	Sell	33,188 -40,888	-55%	-$1M	0.04%	181
2022 Q3	$1.43M	Buy	74,076 +33,530	+83%	+$852K	0.05%	175
2022 Q2	$1.05M	Buy	40,546 +414	+1%	+$9.66K	0.03%	227
2022 Q1	$1.04M	Buy	40,132 +576	+1%	+$17.1K	0.02%	275
2021 Q4	$1.61M	Sell	39,556 -8,135	-17%	-$319K	0.03%	230
2021 Q3	$2.06M	Buy	47,691 +9,332	+24%	+$404K	0.04%	199
2021 Q2	$1.79M	Sell	38,359 -798	-2%	-$36.3K	0.03%	232
2021 Q1	$1.87M	Sell	39,157 -22,804	-37%	-$1.23M	0.03%	199
2020 Q4	$1.75M	Sell	61,961 -6,847	-10%	-$223K	0.04%	207
2020 Q3	$2.6M	Buy	68,808 +49,113	+249%	+$2.11M	0.08%	146
2020 Q2	$715K	Buy	+19,695	New	+$661K	0.03%	224

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

ETF Managers Group's VIR Position: Q1 2023 in Review

ETF Managers Group increased its Vir Biotechnology (VIR) stake by 3% in Q1 2023, buying an estimated $25.6K and bringing the position to 34,187 shares worth $796K. The position accounts for 0.03% of the portfolio, ranked #272.

ETF Managers Group first reported a position in VIR in Q2 2020 and has held it in 12 quarters since. The position peaked at $2.6M in Q3 2020. 232 funds tracked by Wall St. Rank hold VIR as of Q1 2023.

ETF Managers Group held 34,187 shares of Vir Biotechnology worth $796K as of Q1 2023.
ETF Managers Group bought 999 Vir Biotechnology shares in Q1 2023, an estimated $25.6K.
Vir Biotechnology made up 0.03% of ETF Managers Group's portfolio in Q1 2023, its #272 holding.
ETF Managers Group first reported a position in Vir Biotechnology in Q2 2020 and has held it in 12 quarters since.
ETF Managers Group's Vir Biotechnology position peaked at $2.6M in Q3 2020.
232 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.